Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
-- Application allowed with broad method claims that are Orange Book-listable --
-- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in
The allowed claims cover methods of contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel. Evofem expects the resulting patent will be Orange Book-listable. The patent, when issued, will be Evofem's fifth patent for Phexxi in the United States.
"We are pleased that our
Phexxi is the first and only FDA-approved locally-acting contraceptive gel. It is applied zero-to-60 minutes before intercourse and works, without hormones, by maintaining the natural vaginal biome with a pH that is naturally inhospitable to sperm.
Phexxi net sales have increased in each consecutive year since it was launched in 2020. Key growth drivers for 2024 include expanded use of Phexxi in women of reproductive age who take oral contraceptives in conjunction with GLP-1 agonists like Mounjaro and Zepbound. These drugs may make oral birth control pills less effective at certain points in the dosing schedule. Patients are advised to use a supplemental method to prevent unintended pregnancy during these times.1,2 A non-systemic, non-hormonal method, like Phexxi, is a logical choice for these women.
About
Phexxi® is a registered trademark of
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's
Sources
1 Zepbound Prescribing Information. https://uspl.lilly.com/zepbound/zepbound.html#pi
2 Zepbound Safety Summary with Warnings. https://zepbound.lilly.com/
Media Contact
media@evofem.com
Investor Contact
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-strengthens-phexxi-intellectual-property-with-new-composition-of-matter-patent-from-uspto-302120143.html
SOURCE